Ethyl Acetate Fraction of Eclipta Alba: A Potential Phytopharmaceutical Targeting Adipocyte Differentiation

The 2017 study explored the potential of the ethyl acetate fraction of Eclipta alba (EA) in combating fat cell formation and lipid disorders. The EA fraction notably inhibited the differentiation of fat cells in both mouse and human cell models, and it also induced cell cycle arrest and disrupted a key signaling pathway for cell differentiation. Furthermore, when administered to Syrian golden hamsters on a high-fat diet, EA significantly reduced blood lipid levels, suggesting its effectiveness in treating dyslipidemia. The presence of bioactive compounds, including wedelolactone and its derivatives, was confirmed, which are known for their anti-adipogenic properties. The study concluded that EA from Eclipta alba holds promise as a phytopharmaceutical agent for obesity treatment, although the number of subjects or samples was not specified in the summary.